National Lung Screening Program – more than just looking for cancer

13th April 2026, NIA Diagnostic Imaging

lung health

Lung cancer remains the leading cause of cancer-related mortality in Australia, accounting for over 8,500 deaths each year. The National Lung Cancer Screening Program (NLCSP) is a major step forward, using low-dose CT scans to detect cancer earlier in those at high risk. This initiative is designed to reduce mortality and support better outcomes through early intervention.…

Should we screen for helicobacter infection in patients on aspirin?

29th September 2025, A/Prof Chee L Khoo

aspirin related GI bleeding

I must admit that I have been doing this for many years on an ad hoc basis. I have been screening for helicobacter pylori (HP) infection in patients who need to be on aspirin (primary or secondary prevention of coronary artery disease). This isn’t what is recommended in any cardiovascular (CV) disease guidelines until recently but the evidence is not robust.…

Reducing LDL-C for brain health – how low do we need to go?

27th April 2025, A/Prof Chee L Khoo

how low should LDL-C be?

We recently looked at the LDL-C levels needed to stabilise plaque progression and the LDL-C levels needed to cause plaque regression. Plaque stabilisation and regression leads to reduction in cardiovascular events. Dyslipidaemia (especially LDL-C) is also associated with cognitive impairment and dementia and reducing those numbers with statin therapy reduces the risk.…

CKD – high protein intake or not?

12th September 2024, A/Prof Chee L Khoo

Protein

Inadequate protein intake in older adults may cause impairments of muscle mass and muscle function as well as impairment in immune function. Higher protein intake has been associated with increased muscle mass and strength, slower rate of bone loss, higher bone mineral density, lower risk of frailty, and improved cardiovascular function and recovery from illness (including wound healing) (1,2).…

Does salt reduction really reduce BP and CVD?

21st July 2024, A/Prof Chee L Khoo

Salt intake

I know this what we were all led to believe – high salt intake independently contributes to high blood pressure and ultimately, increases cardiovascular disease (CVD). Further, reducing salt intake will reduce blood pressure and thence, cardiovascular disease. We may sometimes wonder how strong the evidence for both statements is. As we ponder about the associations, we may or may not push the message of salt reduction as strongly as we should.…

Intravenous iron for iron deficiency – can you give too much?

13th July 2024, A/Prof Chee L Khoo

Iron infusion

Iron deficiency can occur in a number of scenarios. It can arise from blood loss (gastrointestinal, gynaecological), inadequate dietary sources or limited absorption in inflammatory conditions (e.g CKD, heart failure or diabetes). Oral iron supplements not only can have annoying GI side effects but absorption is poor under the best of conditions.…

The 4th Pillar in treatment of CKD

31st May 2024, A/Prof Chee L Khoo

CKD

Renin-angiotensin system (RAS) inhibitors and SGLT2 inhibitors have been the cornerstone treatment of chronic kidney disease (CKD) for many years now. They have been shown to protect kidneys and at the same time reduce adverse cardiovascular outcomes. Finerenone was recently shown to do the same. These three agents are now the guideline-directed three pillars in the treatment of CKD.…

Colchicine to reduce CVD – is it prime time yet?

12th May 2024, A/Prof Chee L Khoo

ASCVD

We are used to using colchicine for acute treatment of gout but colchicine has also proven itself a key pharmacotherapy in the treatment of cardiovascular conditions such as pericardial disease (1), post-operative atrial fibrillation (2) and coronary artery disease (3). Colchicine disrupts the inflammatory response in acute gout but the inflammatory pathways that colchicine acts on are also found in other inflammatory diseases including coronary artery disease.…

BP control – a novel way to address medication adherence?

24th February 2024, A/Prof Chee L Khoo

BP Control

We all know how important it is for BP control in prevention cardiovascular, cerebrovascular and renal complications. We are also aware of the difficulty is improving medication adherence. We have a broad range of effective BP lowering medications covering diverse classes of medications. Anti-hypertensives work only if our patients take them regularly.…

Amiodarone toxicity – nastier than you think

13th January 2024, Conjoint A/Prof Chee L Khoo

Amiodarone toxicity

Amiodarone started life as an anti-angina drug but it’s used primarily for its anti-arrhythmic properties these days. That’s not because it is such a good anti-arrhythmic agent (AAD) but because there just aren’t that many good and safe anti-arrhythmic agents around. We are all aware of amiodarone’s thyroid effects (hypo or hyper) and we monitor them closely as long as they are on amiodarone.…

Marathon running – putting science into practice

27th December 2023, A/Prof Chee L Khoo

Endurance athlete

When we think about extreme physical activity (EPA) such as marathon running, apart from the perceived issue of wearing out knee and hip joints (that’s another issue, another day), we think about the cardiovascular risks or benefits that comes with this intense physical activity. We explored the issue of marathon running and cardiovascular risks 9 months ago here.…

CKD in T1D – any advances in management?

27th December 2023, A/Prof Chee L Khoo

CKD

Not surprisingly, if dysglycaemia is the major contributor to microvascular complications in type 2 diabetes (T2D), the same complications must plaque our patients with type 1 diabetes (T1D. However, we haven’t had many major advances in the management for chronic kidney disease (CKD) and cardiovascular disease (CVD) in patients with T1D for decades.…